Bühler F R, Müller F B
J Hypertens Suppl. 1986 Dec;4(5):S435-40.
Recent large-scale antihypertensive treatment trials primarily emphasize the quality of blood pressure control for reduction of cerebrovascular accidents as well as for myocardial infarction, practically irrespective of the type of drug used. Therefore, the best drug that normalizes blood pressure without adverse effects should be sought. On the basis of studies demonstrating cellular membrane and calcium homoeostatic derangements, and an age-dependent transition of overall cardiovascular regulation and peripheral vasoconstrictor forces during the course of essential hypertension, an alternative treatment concept is proposed: angiotensin converting enzyme inhibitors or beta-blockers can primarily be used in younger patients and those with a high renin, while calcium antagonists are used in place of diuretics in older, low-renin or black patients. Age-oriented two-way drug selection enables normalization of blood pressure without untoward effects in about 80% of patients with essential hypertension, and helps to optimize drug combinations in those patients who are difficult to treat.
近期大规模降压治疗试验主要强调控制血压质量以降低脑血管意外以及心肌梗死的发生率,几乎与所用药物类型无关。因此,应寻找能使血压正常化且无不良反应的最佳药物。基于一些研究表明细胞膜和钙稳态紊乱,以及在原发性高血压病程中整体心血管调节和外周血管收缩力随年龄的转变,提出了一种替代治疗理念:血管紧张素转换酶抑制剂或β受体阻滞剂主要用于年轻患者以及肾素水平高的患者,而在老年、低肾素或黑人患者中,钙拮抗剂可替代利尿剂使用。以年龄为导向的双向药物选择可使约80%的原发性高血压患者血压正常化且无不良影响,并有助于优化难治性患者的药物组合。